Ventricular septal defect

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Retrieved on: 
Wednesday, April 3, 2024
Ventricular septal defect, DCN, Disease, HIV, Patient, CTD, Connective tissue disease, Death, Parkinson's disease, Imatinib, IND, Pulmonary hypertension, Woman, Therapy, Heart, Safety, Division, WHO, HIV/AIDS, Stomach, PAH, FDA, Blood, Food, Pharmaceutical industry

The meeting will be held on April 5, 2024, with meeting results to be reported following receipt of the formal meeting minutes.

Key Points: 
  • The meeting will be held on April 5, 2024, with meeting results to be reported following receipt of the formal meeting minutes.
  • “Following our pre-NDA discussion with the FDA related to the path to approval for IkT-001Pro in up to 11 blood and stomach cancers in January, we requested an additional FDA meeting with the Division of Cardiology and Nephrology to discuss Pro as a treatment for Pulmonary Arterial Hypertension,” said Dr. Milton Werner, President and Chief Executive Officer of Inhibikase.
  • “PAH is a rare condition that primarily afflicts women between the ages of 30 and 60 and can lead to premature heart failure and death.
  • We believe that Pro may be a be a safer and better tolerated therapeutic option for imatinib treatment in PAH.

New survey uncovers lack of awareness around heart valve disease and risk factors among women

Retrieved on: 
Sunday, April 7, 2024
Diagnosis, Health, Cardiovascular disease, Ventricular septal defect, Organization, Prevalence, Coronary artery disease, Disease, Health equity, Risk, Patient, Ageing, Knowledge, Aortic stenosis, Research, Female, Medtronic, MD, Male, American College, TAVR, Fatigue, Dietary supplement

DUBLIN, April 7, 2024 /PRNewswire/ -- Medtronic plc, a global leader in healthcare technology, today unveiled topline findings of its comprehensive survey on women's perceptions and knowledge of risk factors, treatment patterns, and preventive care practices related to heart valve disease. The survey is endorsed by Women as One and was conducted by Wakefield Research sampling 1,000 women in the United States (U.S.) aged 50 and older.

Key Points: 
  • "Heart valve disease awareness deserves broader attention in the U.S., especially considering many women aged 50 and older are at an increased risk of developing the disease.
  • This survey shines a light on the need for increased awareness, early detection, and access to appropriate care for women."
  • Findings from the survey highlight:
    There is a lack of awareness among women about the risks of aortic stenosis (AS) and cardiovascular disease.
  • Despite the prevalence of cardiovascular disease amongst women, awareness is low, with 26% of women not having heard of any of the most common heart-related conditions such as coronary artery disease, congenital heart disease, heart valve disease, or AS, and only 30% of women aged 50 and older having heard of AS.

Orphan designation: Allogeneic cultured postnatal thymus-derived tissue Treatment of CHARGE syndrome, 26/02/2019 Positive

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Gene, Brain, Growth, Coloboma, Thymus, Patient, Committee, Knowledge, CHD7, Regulation, Child, Ventricular septal defect, EMA, IRIS, Eye, European, Infection, Therapy, COMP, Heart, Safety, European Commission, Spine, CHARGE syndrome, Nose, Genetic disorder, Sleep, Hearing, Medicine, Pharmaceutical industry

Orphan designation: Allogeneic cultured postnatal thymus-derived tissue Treatment of CHARGE syndrome, 26/02/2019 Positive

Key Points: 


Orphan designation: Allogeneic cultured postnatal thymus-derived tissue Treatment of CHARGE syndrome, 26/02/2019 Positive

Orphan designation: Allogeneic cultured postnatal thymus-derived tissue Treatment of DiGeorge syndrome, 26/02/2019 Positive

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Learning, Vitamin D, Medicine, DiGeorge syndrome, Seizure, Patient, Committee, Knowledge, Regulation, Ventricular septal defect, Palate, EMA, IRIS, Mouth, European, Infection, COMP, Heart, Safety, European Commission, Anatomical pathology, Pharmaceutical industry

Overview

Key Points: 
  • Overview
    On 26 February 2019, orphan designation (EU/3/19/2135) was granted by the European Commission to Enzyvant Therapeutics Ireland Limited, Ireland, for allogeneic cultured postnatal thymus-derived tissue (also known as RVT-802) for the treatment of DiGeorge syndrome.
  • DiGeorge syndrome is a long-term debilitating condition that may be life-threatening particularly because of the heart problems and serious infections.
  • At the time of application for orphan designation, there was no satisfactory treatment for DiGeorge syndrome authorised in the EU.
  • Orphan designation of the medicine had been granted in the United States for treatment of patients with complete DiGeorge anomaly.

Wayne J. Franklin, M.D., F.A.C.C., named senior vice president of the Children’s National Heart Center

Retrieved on: 
Wednesday, March 13, 2024
Internal medicine, Obstetrics, Ventricular septal defect, Gynaecology, Cardiology, Pediatric nursing, Education, Pulmonary hypertension, Patient, Duke University, SVP, Research, Electrophysiology, University, Pregnancy, Quality, Pediatrics, Hospital, Safety, Division, Children's National Hospital, Baylor University, Williams College

Washington, D.C., March 13, 2024 (GLOBE NEWSWIRE) -- Children's National Hospital has appointed Wayne J. Franklin, M.D., F.A.C.C., as the new senior vice president (SVP) of the Children’s National Heart Center .

Key Points: 
  • Washington, D.C., March 13, 2024 (GLOBE NEWSWIRE) -- Children's National Hospital has appointed Wayne J. Franklin, M.D., F.A.C.C., as the new senior vice president (SVP) of the Children’s National Heart Center .
  • Dr. Franklin currently serves as co-director, medical director of Quality and endowed chair in the Center for Heart Care and associate director of the Adult Congenital Heart Disease Program at Phoenix Children’s.
  • “I look forward to leading the exceptional Heart Center team at Children’s National, as we contribute to advancing pediatric cardiac care and research,” said Dr. Franklin.
  • “Together with our Heart Center leadership team, he will ensure we’re meeting the highest standards of safety, quality and innovative care for our patients and families.”
    The Children’s National Heart Center is a multidisciplinary center that provides high-quality and innovative pediatric cardiac care.

Fabric Genomics Partners with Intermountain Children’s Health to Enhance Precision Diagnosis of Infants and Children Using Whole Genome Sequencing from Broad Clinical Labs

Retrieved on: 
Wednesday, March 13, 2024
Health Technology, Data Management, Other Health, Technology, Practice Management, Hospitals, Genetics, Parenting, Artificial Intelligence, Baby, Maternity, Biotechnology, Science, Software, Other Science, Consumer, Health, Diagnosis, WGS, Genomics, Ventricular septal defect, Database, Entrepreneurship, CICU, DSM-IV codes, Intelligence, Partnership, Intermountain, Physician, Patient, Knowledge, Research, Intermountain Health, Infant, University, Doctor of Philosophy, MD, CHD, Medicine, Phenotype, Hospital, Whole genome sequencing, Multimedia, Pediatrics, Nursing

The sample-to-report genome service enables healthcare professionals to identify genetic disorders with unprecedented speed and precision and to tailor treatment plans to the unique genetic makeup of each infant.

Key Points: 
  • The sample-to-report genome service enables healthcare professionals to identify genetic disorders with unprecedented speed and precision and to tailor treatment plans to the unique genetic makeup of each infant.
  • Offered by partners Broad Clinical Labs and Fabric Genomics, the sample-to-report genomic analysis service makes whole genome sequencing (WGS) and diagnosis accessible to healthcare systems who may not currently have genomics infrastructure and expertise in-house.
  • The partnership between Broad Clinical Labs and Fabric Genomics addresses the critical need for affordable, accurate genomic insights, particularly for infants undergoing surgical repair of congenital heart disease (CHD).
  • "We are excited to integrate the Broad Clinical Labs’ whole genome sequencing service and Fabric’s Enterprise software platform into the clinical workflow within our pediatric cardiac intensive care unit (CICU).

CHLA Researchers Find That Length of Opioid Treatment for Hospitalized Infants Differs by Institution and Geography

Retrieved on: 
Tuesday, March 12, 2024
Other Health, Research, Pharmaceutical, Family, Consumer, Hospitals, Children, Science, Surgery, Baby, Maternity, Other Science, Health, JAMA Network Open, Ventricular septal defect, Risk, Infant, Prescription, MD, Methadone, MSHS, Hydromorphone, Morphine, Multimedia, Paper, Policy, Intubation, Fentanyl

View the full release here: https://www.businesswire.com/news/home/20240312681130/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240312681130/en/
    In a study published in JAMA Network Open, researchers at Children’s Hospital Los Angeles found the opioid treatment that critically ill, hospitalized infants received depended on their location.
  • The length of time the infants were prescribed opioids differed by geographic region across the U.S.— the Northeast, South, Midwest or West.
  • “Additionally, prolonged opioid exposure in high-risk hospitalized infants has been implicated in worsening neurodevelopmental outcomes,” Dr. Keane says.
  • During their hospital stay, 76% of infants were prescribed opioids such as fentanyl, morphine and hydromorphone, and about 8% received methadone.

Global Pediatric Interventional Cardiology Market Forecast 2024-2030: PIC Market Forecast for 6.36% CAGR Between 2024 to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 29, 2024
General Health, Health, Cardiology, Heart, Incidence, Procedure, Catheter, Birth defect, Investment, Physician, Moyamoya disease, Congenital heart defect, Projection, VSD, Angioplasty, Prevalence, CHD, Coronary thrombosis, Atherectomy, Patient, Stent, Ventricular septal defect, CDC, Catheter ablation, Research, Medical imaging

The Pediatric Interventional Cardiology Market is forecasted to reach US$ 3.91 Billion through 2030.

Key Points: 
  • The Pediatric Interventional Cardiology Market is forecasted to reach US$ 3.91 Billion through 2030.
  • The pediatric interventional cardiology market proportion is expanding swiftly, driven by the rising prevalence of cardiac disorders in children and technological advancements.
  • The Stents segment is anticipated to dominate the global pediatric interventional cardiology market throughout the forecast period.
  • The comprehensive infrastructure of hospitals, coupled with their ability to provide diverse pediatric cardiology services, positions them as key contributors to the growth and development of the Pediatric Interventional Cardiology market.

MEDI8897 (Nirsevimab): An Investigational Long-Acting Antibody that Protects all Infants through their First RSV Season with a Single Dose - Market Size, Forecasts, and Market Insight 2019-2032 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024
Health, Pharmaceutical, RSV, AstraZeneca, Immunization, FDA, SWOT, EU4, Nirsevimab, Sanofi, Infant, Ventricular septal defect, Disease, Research, Immune system, Pharmaceutical industry

The report provides comprehensive insights about MEDI8897 for Respiratory syncytial virus (RSV) in the seven major markets.

Key Points: 
  • The report provides comprehensive insights about MEDI8897 for Respiratory syncytial virus (RSV) in the seven major markets.
  • MEDI8897 (Nirsevimab) is an investigational long-acting antibody that protects all infants through their first RSV season with a single dose.
  • Nirsevimab is an immunization that provides direct prophylactic RSV protection to all infants via an antibody to help prevent LRTI caused by RSV.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MEDI8897 in RSV.

Children’s Hospital Los Angeles Unveils New Fetal Cardiac Clinic

Retrieved on: 
Tuesday, February 13, 2024
Nursing, Cardiology, Children, Baby, Maternity, Health, General Health, Family, Hospitals, Surgery, Consumer, Parenting, Master of Science, Division, CHLA, Multimedia, MSN, RN, Magnetic resonance imaging, CCRN, Ventricular septal defect, Pregnancy, Learning, Child, Risk, MHA, FRCPC, Circulant matrix, MHO, Patient, Senior counsel, Social, Heart, Diagnosis, Test management, MRI, Hospital

Children’s Hospital Los Angeles has opened its new Fetal Cardiac Clinic , a unique space for expectant mothers and the fetal patient population to continue receiving the highest level of comprehensive care during pregnancy, birth and beyond.

Key Points: 
  • Children’s Hospital Los Angeles has opened its new Fetal Cardiac Clinic , a unique space for expectant mothers and the fetal patient population to continue receiving the highest level of comprehensive care during pregnancy, birth and beyond.
  • View the full release here: https://www.businesswire.com/news/home/20240213588362/en/
    The Heart Institute at Children's Hospital Los Angeles celebrates the opening of its new Fetal Cardiac Clinic.
  • “With the launch of our new Fetal Cardiac Clinic, we now have a dedicated space that can serve as a one-stop shop for families in need of comprehensive prenatal diagnostic testing and counseling for cardiac anomalies.”
    CHLA’s state-of-the-art Fetal Cardiac Clinic features over 3,000 square feet of space and three scanning rooms dedicated to fetal cardiology.
  • Services provided at the CHLA Fetal Cardiac Clinic include:
    To learn more about CHLA’s Fetal Cardiac Clinic, visit CHLA.org/FetalCardiology or call 323-361-7398.